Introducing the First-Ever Treatment for Canine Parvovirus developed by Elanco Animal Health.
Canine parvovirus is one of the leading causes of illness and fatalities in dogs around the world with a mortality rate as high as 91% if left untreated and an estimated 900 cases are diagnosed a day in the U.S., totaling 330,000 cases annually. While vaccination has been the primary preventive measure, there have been no antiviral treatment options for infected dogs until now. Enter the Canine Parvovirus Monoclonal Antibody (CPMA) – the first and only USDA-conditionally approved, one-dose treatment for parvovirus in dogs.
Canine parvovirus is an extremely infectious disease that attacks the intestinal lining and can be fatal if left untreated. Puppies are at a high risk of contracting the virus until they have been vaccinated completely, while unvaccinated dogs are also at risk.
If you witness any of the following symptoms, contact Pennsauken Animal Hospital & Urgent Care right away and inquire about canine parvovirus and CPMA as a potential treatment option:
Loss of appetite
Recently, Dr. Rippie’s Helping Paws assisted a parvo-positive dog named Digit in need. Digit was discovered tied to a fence, undernourished, with a missing toe, showing signs of prolonged crate confinement, and unfortunately tested positive for parvo. Digit received treatment at Pennsauken Animal Hospital, including the new injectable treatment and supportive care. The staff observed Digit's quicker recovery compared to previous cases without the new medication. Digit's symptoms diminished faster, and the dog regained energy and playfulness sooner.
This new treatment option is showing great promise, and reduces the amount and intensity of care needed, reducing hospitalization times or even avoiding hospitalization if treated early. This treatment involves a single IV injection that can be administered with standard supportive care for dogs that test positive.
Don't hesitate to contact Pennsauken Animal Hospital & Urgent Care, as early treatment is crucial.